Royalty Pharma plc (RPRX) is a global leader in acquiring revenue-producing biopharmaceutical royalty interests. Founded in 1996 and headquartered in New York City, the company plays a pivotal role in the biopharma industry by collaborating with innovation-focused companies, research institutions, and inventors though its unique, capital-efficient funding model. With the stock symbol RPRX, Royalty Pharma has been listed on the NASDAQ stock exchange since June 2020.
Royalty Pharma offers a new, collaborative model for research funding. Its financial model is a refreshing alternative to the traditional pharmaceutical industry funding structures. Rather than investing in the expensive, prolonged, and risk-laden process of drug development, Royalty Pharma acquires existing royalties from the inventors, developers, and financiers of drugs. This structure allows the original inventor to monetize their innovative accomplishments and reinvest in fresh research and development endeavors, while Royalty Pharma takes on the risk and potential profit from the drug’s future sales.
Over the past two and a half decades, Royalty Pharma's business model has proven to be financially successful, leading the company to be seen as a pioneer in the biopharma industry. The company's portfolio includes some of the industry's most lucrative therapeutics developed by leading biopharmaceutical companies worldwide. These therapeutics cover a broad range of areas including oncology, neurology, HIV, cardiology, diabetes and many others, reflecting the company's commitment to improving patient lives.
Through strategic partnerships and royalty acquisitions, Royalty Pharma has created a stable and notably diversified royalty portfolio. This portfolio, coupled with its distinctive business model, has positioned the company to offer consistent financial performance with the unique ability to reinvest in next-generation therapies. Overall, Royalty Pharma plc exemplifies a novel and thriving approach to healthcare investment by providing essential funding for medical research while delivering returns to its shareholders.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Royalty Pharma (NASDAQ:RPRX) recently achieved a new 52-week high of $62.58, with analysts maintaining a "Buy" rating and an average target price of $60.86. Despite revenue missing estimates, the company surpassed EPS expectations in its latest quarterly results. Royalty Pharma also announced a quarterly dividend of $0.235 per share, though insiders have sold a significant amount of stock recently.
Headlands Technologies LLC has acquired a new stake in Royalty Pharma PLC, purchasing 90,729 shares valued at approximately $5.09 million during the second quarter. Other institutional investors have also increased their holdings in the biopharmaceutical company, which has reported quarterly EPS of $1.32, beating estimates, despite revenue falling short of consensus forecasts. Analysts generally maintain a positive outlook for Royalty Pharma, with an average price target of $60.86.
Odyssean LLC increased its stake in Royalty Pharma PLC (NASDAQ:RPRX) by 65.3% in Q2 2026, acquiring an additional 21,401 shares, bringing its total holdings to 54,179 shares valued at $3.04 million. The biopharmaceutical company reported Q2 EPS of $1.32, surpassing estimates, though revenue of $674.14 million missed expectations. Analysts maintain a bullish outlook with an average price target of $60.86, and Royalty Pharma declared a quarterly dividend of $0.235, representing a 1.5% annualized yield.
Christopher Hite, EVP and Chairman of Partnering at Royalty Pharma plc, sold 100,000 Class A Ordinary Shares for approximately $5.99 million under a 10b5-1 trading plan. Additionally, he donated 16,800 shares to Lehigh University. Following these transactions, Hite retains significant direct and indirect ownership in the company.